Journal of the American Academy of Dermatology · 2016
Hidradenitis suppurativa (HS): An unrecognized paradoxical effect of biologic agents (BA) used in chronic inflammatory diseases.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Faivre Coline, Villani Axel Patrice, Aubin François, Lipsker Dan, Bottaro Martine, Cohen Jean-David, Durupt François, Jeudy Géraldine, Sbidian Emilie, Toussirot Eric, Badot Valérie, Barbarot Sébastien, Debarbieux Sébastien, Delaporte Emmanuel, Goegebeur Guetty, Morel Jacques, Nassif Aude, Duru Gérard, Jullien Denis, French Society of Dermatology and Club Rheumatisms and Inflammation
Аннотация
BACKGROUND: Paradoxical hidradenitis suppurativa (HS) induced by biologic agents (BA) is scarcely reported.
OBJECTIVE: We sought to describe the clinical characteristics and outcome of patients developing paradoxical HS under BA.
METHODS: This was a multicenter nationwide retrospective study asking physicians to report all cases of HS, confirmed by a dermatologist, occurring during treatment of an inflammatory disease by a BA.
RESULTS: We included 25 patients (15 inflammatory rheumatism, 9 Crohn's disease, 1 psoriasis) treated by 5 BA (adalimumab = 12, infliximab = 6, etanercept = 4, rituximab = 2, tocilizumab = 1). Median duration of BA exposure before HS onset was 12 (range 1-120) months. Patients were mostly Hurley stage I (n = 13) or II (n = 11). Simultaneously to HS or within 1 year, 11 patients developed additional inflammatory diseases, including paradoxical reactions (psoriasis = 9, Crohn's disease = 3, alopecia areata = 1, erythema elevatum diutinum = 1). Complete improvement of HS was more frequently obtained after BA discontinuation or switch (n = 6/10, 60%) rather than maintenance (n = 1/14, 7%). Reintroducing the same BA resulted in HS relapse in 3 of 3 patients.
LIMITATIONS: Retrospective nature and lack of complete follow-up for some patients are limitations.
CONCLUSION: HS is a rare paradoxical adverse effect of BA, but fortuitous association cannot be excluded in some cases. We observed a trend toward better outcome when the BA was discontinued or switched.
OBJECTIVE: We sought to describe the clinical characteristics and outcome of patients developing paradoxical HS under BA.
METHODS: This was a multicenter nationwide retrospective study asking physicians to report all cases of HS, confirmed by a dermatologist, occurring during treatment of an inflammatory disease by a BA.
RESULTS: We included 25 patients (15 inflammatory rheumatism, 9 Crohn's disease, 1 psoriasis) treated by 5 BA (adalimumab = 12, infliximab = 6, etanercept = 4, rituximab = 2, tocilizumab = 1). Median duration of BA exposure before HS onset was 12 (range 1-120) months. Patients were mostly Hurley stage I (n = 13) or II (n = 11). Simultaneously to HS or within 1 year, 11 patients developed additional inflammatory diseases, including paradoxical reactions (psoriasis = 9, Crohn's disease = 3, alopecia areata = 1, erythema elevatum diutinum = 1). Complete improvement of HS was more frequently obtained after BA discontinuation or switch (n = 6/10, 60%) rather than maintenance (n = 1/14, 7%). Reintroducing the same BA resulted in HS relapse in 3 of 3 patients.
LIMITATIONS: Retrospective nature and lack of complete follow-up for some patients are limitations.
CONCLUSION: HS is a rare paradoxical adverse effect of BA, but fortuitous association cannot be excluded in some cases. We observed a trend toward better outcome when the BA was discontinued or switched.
Предметные рубрики MeSH
AdalimumabAdolescentAdultAnti-Inflammatory Agents, Non-SteroidalAntibodies, Monoclonal, HumanizedArthritisBiological ProductsCrohn DiseaseDrug EruptionsDrug SubstitutionEtanerceptFemaleHidradenitis SuppurativaHumansInfliximabMaleMiddle AgedPsoriasisRecurrenceRetrospective StudiesRituximabWithholding TreatmentYoung Adult